Related Experiment Video
Updated: Aug 6, 2026

Automated Hospital Room Disinfection Utilizing a Novel Aerosolized Hydrogen Peroxide Microdroplet Disbursing Technology
Published on: February 24, 2026
Continuous Aerosolized Albuterol Treatment for Status Asthmaticus on the General Care Floor: A Quality Improvement
Kailey A Remien1, Charles Hardy2, Karen Allen3,4
1From the Division of Critical Care Medicine, Nationwide Children's Hospital, Columbus, Ohio.
Insights
Continuous aerosolized albuterol (CAA) can be safely given on general care floors for pediatric asthma, reducing intensive care unit (PICU) hours. This quality improvement project demonstrated successful expansion of CAA use outside the PICU.
Area of Science:
- Pediatric pulmonology
- Quality improvement science
- Healthcare management
Background:
- Asthma is a major cause of pediatric hospitalization in the US.
- Continuous aerosolized albuterol (CAA) is effective for severe asthma exacerbations but typically limited to intensive care settings.
- Expanding CAA to general care floors can improve resource utilization.
Purpose of the Study:
- To assess the feasibility and safety of expanding Continuous Aerosolized Albuterol (CAA) use to the general care floor (GCF) for pediatric patients with status asthmaticus.
- To monitor treatment uptake, adherence to protocol, and safety outcomes of GCF-based CAA.
- To evaluate the impact on Pediatric Intensive Care Unit (PICU) resource utilization.
Main Methods:
- A single-center quality improvement project involving children aged 2-18 years with status asthmaticus.
- Implementation of a structured protocol, staff education, and electronic health record updates.
- Monitoring of GCF CAA hours, PICU/emergency transfers, hypotension, and ED length of stay.
Main Results:
- Continuous aerosolized albuterol (CAA) use on the general care floor (GCF) accounted for 17% of total hospital CAA, exceeding the 10% target.
- 72 patients were safely treated on the GCF, with 31% requiring PICU transfer (none emergent).
- The intervention saved 1,017 PICU hours and an estimated $275,600 in costs, without increasing ED length of stay.
Conclusions:
- Continuous aerosolized albuterol (CAA) can be safely administered on the general care floor (GCF) for pediatric asthma exacerbations.
- A structured protocol facilitates safe GCF implementation, reducing PICU resource needs.
- This approach optimizes resource allocation without compromising emergency department efficiency.
Introduction:
Asthma, a leading cause of pediatric hospitalization, affects more than 6 million US children and costs more than $5 billion annually. Continuous aerosolized albuterol (CAA) effectively treats severe exacerbations but is typically reserved for intensive care or emergency settings. This quality improvement project aimed to safely expand CAA use on the general care floor (GCF) by monitoring treatment uptake, protocol adherence, and safety outcomes.
Methods:
This single-center quality improvement project, led by a multidisciplinary team, included children aged 2-18 years with status asthmaticus on CAA who met the inclusion criteria. Interventions involved protocol development, staff education, electronic health record updates, and a resident-led handoff huddle. Primary outcomes were non-pediatric intensive care unit (PICU) CAA hours and the proportion of patients treated on the GCF. Process measures included protocol use and handoff huddles. Balancing metrics included PICU and emergency transfers, fluid-refractory hypotension, and ED length of stay.
Results:
From June 2024 to October 2025, GCF CAA accounted for 17% of total hospital CAA, surpassing the 10% target. ED length of stay remained unchanged, indicating no disruption to workflow. We safely treated 72 patients on the GCF (average CAA duration of 21.6 h); 22 (31%) required PICU transfer; none were emergent transfer. This intervention saved 1,017 PICU hours (42.4 PICU bed-days), equivalent to $275,600 in room-and-board costs. These savings represent a substantial reduction in PICU resource use; however, we did not conduct a formal cost-effectiveness analysis.
Conclusions:
CAA can be safely administered in the GCF following a structured protocol, reducing the need for PICU resources without adversely affecting ED care efficiency.
Related Concept Videos
Asthma-IV: Nursing Management
First, in...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
COPD: Management Using Bronchodilators and Corticosteroids
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Inhaled Medications
Cardiopulmonary Resuscitation II: ACLS Airway Management
